Bausch + Lomb Corporation ( (BLCO) ) has released its Q3 earnings. Here is a breakdown of the information Bausch + Lomb Corporation presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bausch + Lomb Corporation is a leading global eye health company, operating in the vision care, pharmaceuticals, and surgical segments, dedicated to enhancing vision care worldwide. In its latest earnings report for the quarter ending September 30, 2025, Bausch + Lomb reported a slight increase in revenues compared to the previous year, with product sales reaching $1.277 billion. However, the company experienced a net loss of $28 million for the quarter, attributed to increased costs and expenses. Key financial metrics showed a rise in operating income to $95 million, despite a significant interest expense of $101 million. Looking ahead, Bausch + Lomb’s management remains focused on strategic initiatives and operational efficiencies to navigate economic challenges and enhance shareholder value.